Buscar
Mostrando ítems 1-10 de 10
Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades
(AIDS, 2022-02)
Background: The prognosis of HIV infection dramatically improved after the introduction of triple antiretroviral therapy 25 years ago. Herein, we report the impact of further improvements in HIV management since then, ...
Pre-Exposure Prophylaxis for viral infections other than HIV
(Infezioni in Medicina, 2022)
The battle against human viral infections has histori-cally relied on two medical strategies, namely vaccines to protect from contagion and antivirals to treat infected patients. In the absence of vaccines, antivirals have ...
News from CROI 2022 – caveats using antiretrovirals as HIV prophylaxis
(AIDS Reviews, 2022)
The annual conference on retroviruses and opportunistic infections was held in Denver, CO, last February. Most sessions were attended by virtual attenders, due to restrictions forced by the COVID-19 surge caused by the ...
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
(Journal of Viral Hepatitis, 2022)
Chronic hepatitis C virus (HCV) infection is major cause of decompensated cirrhosis and liver cancer. The advent of curative new antiviral therapies since year 2015 has dramatically improved the prognosis of HCV patients. ...
Viral hepatitis in persons living with HIV in the post-COVID era
(AIDS reviews, 2023)
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
Coinfection with Viral Hepatitis in HIV patients in 2023
(AIDS reviews, 2023)
According to UNAIDS roughly 1.5 million new HIV infections occur each year worldwide. The number of persons living with HIV (PLWH) is estimated around 38 million globally, of whom 25 million live in Sub-Saharan Africa.
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...
Treatment of hepatitis delta and HIV infection
(Liver International, 2023)
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...
Safety considerations in the management of hepatitis C and HIV co-infection
(Expert Opinion on Drug Safety, 2023)
Introduction: Both HCV and HIV are highly prevalent infections with current estimates of 57 and 38 million people infected worldwide, respectively. Oral antivirals can be curative for HCV and rescue HIV patients from disease ...
Triple Threat: HDV, HBV, HIV Coinfection
(Clinics in Liver Disease, 2023)
First discovered in the late 1970s, hepatitis delta virus (HDV) has emerged as an important driver of decompensated liver disease and hepatocellular carcinoma (HCC) worldwide. HDV requires hepatitis B virus (HBV) for ...